ethyl 3-amino-5-chlorobenzo[b]thiophene-2-carboxylate | 181284-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: ethyl 3-amino-5-chlorobenzo[b]thiophene-2-carboxylate
• 英文别名: Ethyl 3-amino-5-chloro-1-benzothiophene-2-carboxylate；ethyl 3-amino-5-chloro-1-benzothiophene-2-carboxylate
• CAS: 181284-98-0
• 化学式: C₁₁H₁₀ClNO₂S
• 分子量: 255.725
• InChiKey: HNIVAVDDKBZBSV-UHFFFAOYSA-N

物化性质

• 沸点：
  404.3±40.0 °C(Predicted)
• 密度：
  1.407±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-amino-5-chlorobenzo[b]thiophene-2-carboxylate 在 三氯氧磷 作用下， 以 formamide 为溶剂， 反应 19.0h， 生成 4,8-dichloro[1]benzothio[3,2-d]pyrimidine
  参考文献：
  名称：

  [EN] COMPOUND, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE
  [FR] COMPOSÉ, ÉLÉMENT ÉLECTROLUMINESCENT, DISPOSITIF D'AFFICHAGE, DISPOSITIF ÉLECTRONIQUE ET DISPOSITIF D'ÉCLAIRAGE

  摘要：

  该化合物包括苯并呋喃嘧啶骨架或苯并噻吩嘧啶骨架、第一取代基和第二取代基。第一取代基和第二取代基中的每一个都包括呋喃骨架、噻吩骨架或吡咯骨架。第一取代基与包括在苯并呋喃嘧啶骨架或苯并噻吩嘧啶骨架中的嘧啶环键结合。第二取代基与包括在苯并呋喃嘧啶骨架或苯并噻吩嘧啶骨架中的苯环键结合。光发射元件包括该化合物。

  公开号：

  WO2017109637A1
• 作为产物：
  描述：

  巯基乙酸乙酯 、 5-氯-2-氟苯腈 在 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 2.5h， 以88%的产率得到ethyl 3-amino-5-chlorobenzo[b]thiophene-2-carboxylate
  参考文献：
  名称：

  2-（1,3,4-恶二唑-2（3H）-硫酮）-3-氨基-5-芳基噻吩并[2,3-b]吡啶作为DRAK2抑制剂的合成及其构效关系研究

  摘要：

  近年来，DAPK相关的凋亡诱导蛋白激酶2（DRAK2）已成为治疗各种自身免疫性疾病和预防器官移植后移植排斥的有希望的靶标。但是，尚未发现用于发现DRAK2新型小分子抑制剂的药物化学优化方案。导致了苯并噻吩类似物的发现专有化合物文库的筛选，其中显示的亲和常数（ķ d 0.25μ）值中号。芯支架的变化时，可以得到一系列5- arylthieno [2,3-的取代模式的b ]与强的结合亲和力的吡啶（ķ d = 0.008μ中号代表最有力的代表）。这些化合物还显示出在功能生化DRAK2酶测定有前途的活性，与IC 50值的0.029μ中号为最有效的同类。最有效的化合物的选择性分析表明，它们在DAPK激酶家族中缺乏选择性。但是，效力较低的类似物之一是DRAK2的选择性配体，可以用作合成选择性有效的DRAK2抑制剂的起点。

  DOI：

  10.1002/cmdc.201402234

文献信息

• Compound, light-emitting element, display device, electronic device, and lighting device
  申请人：Semiconductor Energy Laboratory Co., Ltd.

  公开号：US10586931B2

  公开（公告）日：2020-03-10

  A compound includes a benzofuropyrimidine skeleton or a benzothienopyrimidine skeleton, a first substituent, and a second substituent. Each of the first substituent and the second substituent includes a furan skeleton, a thiophene skeleton, or a pyrrole skeleton. The first substituent is bonded to a pyrimidine ring included in the benzofuropyrimidine skeleton or a pyrimidine ring included in the benzothienopyrimidine skeleton. The second substituent is bonded to a benzene ring included in the benzofuropyrimidine skeleton or a benzene ring included in the benzothienopyrimidine skeleton. The light-emitting element includes the compound.

  一种化合物包括苯并呋喃嘧啶骨架或苯并噻吩嘧啶骨架、第一取代基和第二取代基。第一取代基和第二取代基中的每一个都包括呋喃骨架、噻吩骨架或吡咯骨架。第一取代基与包括在苯并呋喃嘧啶骨架中的嘧啶环或包括在苯并噻吩嘧啶骨架中的嘧啶环键合。第二个取代基与苯并呋喃嘧啶骨架中的苯环或苯并噻吩嘧啶骨架中的苯环键合。发光元件包括化合物。
• Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[<i>e</i>]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
  作者：Michael D. Meyer、Robert J. Altenbach、Fatima Z. Basha、William A. Carroll、Stephen Condon、Steven W. Elmore、James F. Kerwin、Kevin B. Sippy、Karin Tietje、Michael D. Wendt、Arthur A. Hancock、Michael E. Brune、Steven A. Buckner、Irene Drizin

  DOI：10.1021/jm990567u

  日期：2000.4.1

  In search of a uroselective agent that exhibits a high level of selectivity for the alpha(1A) receptor, a novel series of tricyclic hexahydrobenz[e]isoindoles was synthesized. A generic pharmacophoric model was developed requiring the presence of a basic amine core and a fused heterocyclic side chain separated by an alkyl chain. It was shown that the 6-OMe substitution with R, R stereochemistry of the ring junction of the benz[e]isoindole and a two-carbon spacer chain were optimal. In contrast to the highly specific requirements for the benz[e]isoindole portion and linker chain, a wide variety of tricyclic fused heterocyclic attachments were tolerated with retention of potency and selectivity. In vitro functional assays for the alpha(1) adrenoceptor subtypes were used to further characterize these compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity.
• Compound, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device
  申请人：Semiconductor Energy Laboratory Co., Ltd.

  公开号：US20170186971A1

  公开（公告）日：2017-06-29

  A compound includes a benzofuropyrimidine skeleton or a benzothienopyrimidine skeleton, a first substituent, and a second substituent. Each of the first substituent and the second substituent includes a furan skeleton, a thiophene skeleton, or a pyrrole skeleton. The first substituent is bonded to a pyrimidine ring included in the benzofuropyrimidine skeleton or a pyrimidine ring included in the benzothienopyrimidine skeleton. The second substituent is bonded to a benzene ring included in the benzofuropyrimidine skeleton or a benzene ring included in the benzothienopyrimidine skeleton. The light-emitting element includes the compound.
• Synthesis and Structure-Activity Relationship Studies of 2-(1,3,4-Oxadiazole-2(3<i>H</i>)-thione)-3-amino-5-arylthieno[2,3-<i>b</i>]pyridines as Inhibitors of DRAK2
  作者：Piotr Leonczak、Ling-Jie Gao、Anna Teresa Ramadori、Eveline Lescrinier、Jef Rozenski、Steven De Jonghe、Piet Herdewijn

  DOI：10.1002/cmdc.201402234

  日期：2014.11

  recent years, DAPK‐related apoptosis‐inducing protein kinase 2 (DRAK2) has emerged as a promising target for the treatment of a variety of autoimmune diseases and for the prevention of graft rejection after organ transplantation. However, medicinal chemistry optimization campaigns for the discovery of novel small‐molecule inhibitors of DRAK2 have not yet been published. Screening of a proprietary compound

  近年来，DAPK相关的凋亡诱导蛋白激酶2（DRAK2）已成为治疗各种自身免疫性疾病和预防器官移植后移植排斥的有希望的靶标。但是，尚未发现用于发现DRAK2新型小分子抑制剂的药物化学优化方案。导致了苯并噻吩类似物的发现专有化合物文库的筛选，其中显示的亲和常数（ķ d 0.25μ）值中号。芯支架的变化时，可以得到一系列5- arylthieno [2,3-的取代模式的b ]与强的结合亲和力的吡啶（ķ d = 0.008μ中号代表最有力的代表）。这些化合物还显示出在功能生化DRAK2酶测定有前途的活性，与IC 50值的0.029μ中号为最有效的同类。最有效的化合物的选择性分析表明，它们在DAPK激酶家族中缺乏选择性。但是，效力较低的类似物之一是DRAK2的选择性配体，可以用作合成选择性有效的DRAK2抑制剂的起点。
• [EN] COMPOUND, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE<br/>[FR] COMPOSÉ, ÉLÉMENT ÉLECTROLUMINESCENT, DISPOSITIF D'AFFICHAGE, DISPOSITIF ÉLECTRONIQUE ET DISPOSITIF D'ÉCLAIRAGE
  申请人：SEMICONDUCTOR ENERGY LAB

  公开号：WO2017109637A1

  公开（公告）日：2017-06-29

  A compound includes a benzofuropyrimidine skeleton or a benzothienopyrimidine skeleton, a first substituent, and a second substituent. Each of the first substituent and the second substituent includes a furan skeleton, a thiophene skeleton, or a pyrrole skeleton. The first substituent is bonded to a pyrimidine ring included in the benzofuropyrimidine skeleton or a pyrimidine ring included in the benzothienopyrimidine skeleton. The second substituent is bonded to a benzene ring included in the benzofuropyrimidine skeleton or a benzene ring included in the benzothienopyrimidine skeleton. The light-emitting element includes the compound.

  该化合物包括苯并呋喃嘧啶骨架或苯并噻吩嘧啶骨架、第一取代基和第二取代基。第一取代基和第二取代基中的每一个都包括呋喃骨架、噻吩骨架或吡咯骨架。第一取代基与包括在苯并呋喃嘧啶骨架或苯并噻吩嘧啶骨架中的嘧啶环键结合。第二取代基与包括在苯并呋喃嘧啶骨架或苯并噻吩嘧啶骨架中的苯环键结合。光发射元件包括该化合物。